Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Intermittent PI3Kα/β/δ Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy

ABSTRACT: Examination of gene expression level in tumor tissue or CD8T cell in vehicle, BAY1082439 (Single dose), BAY1082439 daily/intermittent treatment, BAY1082439 treatment release drug treatment group. Examination of gene expression level in CAP2 CAP8 PC3 and LNCaP cell line in vehicle or BAY1082439 treatment. Examination of gene expression level in spleen CD8T cell in vehicle or intermittent BAY1082439 treatment.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE159660 | GEO | 2021/11/23

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Intermittent treatment on exemestane acquired resistance

Project description:Intermittent treatment on exemestane acquired resistance

| PRJNA628626 | ENA

Intermittent Drug Treatment of BRAFV600E Melanoma Cells Delays Resistance by Sensitizing Cells to Rechallenge

Project description:Melanoma patients receiving drugs targeting BRAFV600E and MKK1/2 invariably develop resistance and continue progression, limiting the efficacy of treatment. As an alternative to continuous dosing schedules, intermittent treatment strategies involving intervening periods of drug withdrawal have been proposed to delay resistance. The efficacy of this treatment strategy has been supported by preclinical findings and several clinical case reports. The beneficial effect of intermittent treatment has been attributed to “drug addiction”, in which the cell viability of resistant cells is compromised during periods of drug removal, presumably due to MAPK pathway hyperactivation. However, the cellular and molecular responses to intermittent treatment are still incompletely understood. Here, we investigate effects of intermittent treatment with the BRAFV600E inhibitor, encorafenib, in a metastatic melanoma cell line engineered to express genes conferring resistance to BRAF inhibition. We show that intermittent treatment shows superior growth suppression compared to continuous treatment for resistant cells that substantially reactivate the MAPK pathway. While drug addiction is clearly observable in these cells, it fails to account for the advantageous effects of intermittent treatment. Instead, growth suppression can mainly be explained by resensitization as most cell death is observed upon readdition of drug following periods of drug removal. Gene expression analysis shows that a unique and reversible transcriptional state is induced in intermittently treated cells following periods of drug removal. Thus, we conclude that the beneficial effects of intermittent treatment in our model are best explained by adaptive, non-mutational changes in transcription which confer drug resensitization.

2018-12-01 | GSE117123 | GEO

Intermittent PI3Kα/β/δ Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy

Project description:Intermittent PI3Kα/β/δ Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy

| PRJNA670117 | ENA

Intermittent Hypoxia ageing

Project description:Expression data from mice exposed to intermittent hypoxia and mice reared for 12 months. We used microarrays to analyze the transcriptome of hippocampus from mice exposed to intermittent hypoxia or aged mice.

2016-12-27 | GSE62385 | GEO

Intermittent Hypoxia ageing

Project description:Intermittent Hypoxia ageing

| PRJNA263964 | ENA

Pegvisomant-treated mouse prostate epithelium renal grafts

Project description:PTEN-CaP2 mouse prostate cancer cells were grafted under the kidney capsule of immunocompromised mice. After three weeks, mice were treated with 100 mg/kg pegvisomant (provided by Pfizer) or PBS vehicle 3X weekly for three weeks. Grafts were harvested three days after final treatment, flash frozen, and total RNA was extracted for sequencing.

2022-04-01 | GSE188543 | GEO

Transcriptome analysis of mouse heart under different intermittent fasting conditions

Project description:Various intermittent fasting regimes are popularly being practiced but the scientific understanding for the mechanisms of intermittent fasting remains unclear. Observing the overall transcriptomic changes in specific organs, including heart, may contribute substantially in understanding the diverse effects of intermittent fasting. Our current study further investigate the differential transcriptomic changes in the heart among the different regimes of intermittent fasting as well.

2023-09-27 | GSE133290 | GEO

sham and MI heart transcriptome after 6-week-long light-phase intermittent prednisone or vehicle administration

Project description:Exogenous glucocorticoids interact with the circadian clock, but little attention is paid to their time of intake. Here we investigated the transcriptional effects of prednisone in heart when pulsed as intermittent once-weekly 1mg/kg i.p. dose in WT mice at ZT0 at 2-weeks after sham or myocardial infarction (MI; permanent ligation) surgeries. Aftter 6 weeks of treatment, we performed RNA-seq analysis in myocardial tissue to quantitate gene expression at isoform level.

2022-06-19 | GSE186875 | GEO

Intermittent fasting alters the spatiotemporal atlas of transcriptomes

Project description:Transcription factors may orchestrate the health benefits of intermittent fasting through directing the expression of genome. Here, we find intermittent fasting can spin the spatiotemporal profile of transcription factors, and provide an atlas of transcription factors in biological space, time and feeding regimen.

2022-10-27 | GSE154797 | GEO

Transcription profiling of mouse primary osteoblastic cells after intermittent of continuous treatment with parathyroid hormone to investigate the role of beta-arrestin2

Project description:Role of beta-arrestin2 in response to intermittent or continuous parathyroid hormone (PTH) treatment.

2009-07-20 | E-TABM-624 | biostudies-arrayexpress